FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an agent exhibiting nootropic action. The declared agent contains calcium chloride, sodium chloride, ferric sulphate (II), zinc sulphate, chromium chloride (III) and potassium bromide in certain proportions.
EFFECT: invention provides normalisation of the CNS function ensured by nootropic action.
1 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
DRUG WITH NOOTROPIC EFFECT | 2007 |
|
RU2347580C1 |
CEREBROPROTECTIVE AGENT | 2017 |
|
RU2648451C1 |
CEREBROPROTECTIVE MEDICATION | 2014 |
|
RU2545996C1 |
AGENT SHOWING ANXIOLYTIC ACTION | 2011 |
|
RU2464990C1 |
PREPARATION FOR PREVENTING AND CORRECTING AGE-INDUCED DISORDERS OF HIGHER NERVOUS ACTIVITY | 2005 |
|
RU2296573C2 |
AGENT POSSESSING ANXIOLYTIC, NOOTROPIC, ANTICONVULSANT, ANTIDEPRESSIVE, CEREBRO-PROTECTING ACTIVITY AND ABILITY TO NORMALISE TRANSFER PROCESSES IN BRAIN SYNAPSES | 2007 |
|
RU2335293C1 |
REMEDY POSSESSING NOOTROPIC AND ADAPTATION PROPERTIES AND METHOD FOR PRODUCING THE REMEDY | 1996 |
|
RU2130314C1 |
METHOD OF EXTRACT PREPARING SHOWING ANTIISCHEMIC AND NOOTROPIC ACTIVITY | 1993 |
|
RU2104018C1 |
PHARMACEUTICAL FORMULATION POSSESSING CEREBROPROTECTIVE AND ANTINEUROTIC ACTION | 2013 |
|
RU2535024C1 |
METHOD FOR DIVIDING INBRED MICE INTO TYPOLOGICAL GROUPS WITH HIGHER NERVOUS ACTIVITY SPECIFICITY TAKEN INTO CONSIDERATION | 2006 |
|
RU2316057C1 |
Authors
Dates
2013-02-20—Published
2011-12-14—Filed